[Chemical structure of etanercept, pharmacokinetics and mechanism of action].
The contents of this monography on the current knowledge of etanercept in relationship with psoriasis and psoriatic arthritis is presented. Etanercept was first used in clinical studies in humans in 1992. Reference is made to the current indications approved by the European Medicines Agency. Its chemical structure is described, and the pharmacokinetics data and its mechanism of action are analyzed.
Daudén
E
E
Servicio de Dermatología, Hospital Universitario de la Princesa, Madrid, España. estebandauden@medynet.com
D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000737:chemistry* / Q000494:pharmacology*; D018124:Receptors, Tumor Necrosis Factor / Q000737:chemistry*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000068800:Etanercept